Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study
December 15, 2022 06:59 ET
|
Synlogic, Inc.
Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar...
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
November 30, 2022 16:15 ET
|
Synlogic, Inc.
Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA...
Double Rainbow Announces World’s First Commercial-Scale Biosynthetic Gastrodin, a Natural Analgesic with a Range of Therapeutic Applications
November 28, 2022 09:41 ET
|
DoubleRainbow Biosciences
Lexington, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- DoubleRainbow Biosciences (“Double Rainbow”), a sustainable biotech company harnessing bioengineering to improve the quality of human health,...
Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022 06:59 ET
|
Synlogic, Inc.
Top-line Phase 2 data for phenylketonuria (PKU) demonstrated robust plasma Phe reduction and high response rate; Phase 3 study initiation planned for H1 2023 Clinical readouts for SYNB1353 for...
Synthetic Biology Global Market Report 2022: Extensive Applications Of Synthetic Biology Drive Sector Growth
November 08, 2022 08:43 ET
|
Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Synthetic Biology Market Size, Share & Trends Analysis Report by Product (Enzymes, Cloning Technologies Kits), by Technology (PCR, NGS), by...
DoubleRainbow Biosciences Announces Strategic AI Collaboration with Galixir
November 07, 2022 08:10 ET
|
DoubleRainbow Biosciences
LEXINGTON, MASS., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Double Rainbow, a sustainable health care company harnessing the power of natural evolution through bioengineering to improve the quality of human...
Global Synthetic Biology Market Report 2022: High Potential Opportunities in Agriculture, Manufacturing & Medicine
November 07, 2022 04:28 ET
|
Research and Markets
Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Synthetic Biology Market, By Products, By Application, By Tool, By Technology & By Region- Forecast and Analysis 2022-28" report has been...
Synthetic Biology Market Size Worth $32.73 Bn by 2028 | Vantage Market Research
October 26, 2022 06:04 ET
|
Vantage Market Research
WASHINGTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- According to a report by Vantage Market Research, the Global Synthetic Biology Market was worth USD 10.11 Billion in 2021 and is expected to be worth...
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
October 19, 2022 09:00 ET
|
Telesis Bio
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company,...
Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
October 18, 2022 06:59 ET
|
Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...